A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus

A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus

Blog Article

Abstract The Food and Drug Administration (FDA) has approved k2 grateful dead skis vaccines designed by GSK, copyright and Moderna to protect high-risk populations against respiratory syncytial virus (RSV).These vaccines employ the pre-fusion F (pre-F) protein as the immunogen.In this study, we explored an mRNA vaccine based on a modified pre-F protein called LC2DM-lipid nanoparticle (LC2DM-LNP).This vaccine features a truncated version of the pre-F protein that is anchored to the cell membrane.Our experiments in young and old female mice revealed that the LC2DM-LNP vaccine elicited robust neutralizing antibody titers.

Moreover, LC2DM-LNP prompted a Th1-skewed T-cell immune response in female rodent models.Female cotton rats immunized with LC2DM-LNP demonstrated strong immunity to RSV, without signs of vaccine-enhanced respiratory disease (VERD), even in cases of breakthrough infection.Importantly, when administered to pregnant female cotton rats, LC2DM-LNP ensured the transfer of pre-F-specific antibodies to the offspring and provided protection against RSV without increasing lung inflammation.Our findings 44th ibct patch suggest that LC2DM-LNP could serve as an alternative RSV vaccine candidate for high-risk groups.